Prescription pattern of human recombinant 1-34 parathyroid hormone (teriparatide, forsteo®) in Sweden

被引：0
|
作者：
Ljunggren, O. [1 ]
Toll, A. [2 ]
Myren, K.-J. [2 ]
Mullarney, T. [3 ]
机构：
[1] Uppsala Univ, Dept Med Sci, S-75105 Uppsala, Sweden
[2] Eli Lilly Sweden AB, Stockholm, Sweden
[3] Eli Lillly UK Ltd, Erl Wood, England
来源：
OSTEOPOROSIS INTERNATIONAL | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S71 / S72
页数：2
相关论文
共 50 条
  • [1] Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats
    Agu, RU
    Valiveti, S
    Earles, DC
    Klausner, M
    Hayden, PJ
    Wermeling, DP
    Stinchcomb, AL
    [J]. ENDOCRINE RESEARCH, 2004, 30 (03) : 455 - 467
  • [2] Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review
    Moca Trevisani, Virginia Fernandes
    Riera, Rachel
    Imoto, Aline Mizusaki
    Saconato, Humberto
    Atallah, Alvaro Nagib
    [J]. SAO PAULO MEDICAL JOURNAL, 2008, 126 (05): : 279 - 284
  • [3] Teriparatide [human parathyroid hormone (1-34)] therapy in men with osteoporosis
    Kaufman, J. -M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S184 - S185
  • [4] Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure
    Jiang, YB
    Zhao, JJ
    Mitlak, BH
    Wang, OH
    Genant, HK
    Eriksen, EF
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (11) : 1932 - 1941
  • [5] Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis
    Zanchetta, JR
    Bogado, CE
    Ferretti, JL
    Wang, O
    Wilson, MG
    Sato, M
    Gaich, GA
    Dalsky, GP
    Myers, SL
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (03) : 539 - 543
  • [6] Teriparatide (hPTH-[1-34]) - A recombinant human parathyroid hormone fragment with anabolic actions for the treatment of osteoporosis
    Ashworth, LE
    [J]. FORMULARY, 2002, 37 (03) : 129 - +
  • [7] Teriparatide (biosynthetic human parathyroid hormone 1-34): A new paradigm in the treatment of osteoporosis
    Brixen, KT
    Christensen, PM
    Ejersted, C
    Langdahl, BL
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 94 (06) : 260 - 270
  • [8] High-level production of recombinant human parathyroid hormone 1-34
    Suzuki, Y
    Yabuta, M
    Ohsuye, K
    [J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1998, 64 (02) : 526 - 529
  • [9] The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis
    Orwoll, E
    Scheele, W
    Paul, S
    Adami, S
    Syversen, U
    Diez-Perez, A
    Kaufman, JM
    Clancy, A
    Gaich, G
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (01) : 9 - 17
  • [10] Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers
    Chu, N. N.
    Li, X. N.
    Chen, W. L.
    Xu, H. R.
    [J]. PHARMAZIE, 2007, 62 (11): : 869 - 871
12345